Minimise transmission risk of CJD and vCJD in healthcare settings
- Department of Health
- Part of:
- Creutzfeldt-Jakob disease (CJD): guidance, data and analysis
- 27 November 2012
- Last updated:
- 10 August 2017, see all updates
- Applies to:
Prevention of CJD and vCJD by Advisory Committee on Dangerous Pathogens' Transmissible Spongiform Encephalopathy (ACDP TSE) Subgroup.
PDF, 105KB, 10 pages
PDF, 34.5KB, 12 pages
PDF, 155KB, 22 pages
PDF, 73.1KB, 7 pages
This file may not be suitable for users of assistive technology. Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email email@example.com . Please tell us what format you need. It will help us if you say what assistive technology you use.
PDF, 45.7KB, 4 pages
PDF, 352KB, 12 pages
PDF, 122KB, 16 pages
PDF, 89.1KB, 3 pages
PDF, 636KB, 24 pages
PDF, 99.2KB, 6 pages
PDF, 212KB, 30 pages
PDF, 113KB, 9 pages
PDF, 179KB, 3 pages
PDF, 237KB, 5 pages
PDF, 32.5KB, 1 page
PDF, 109KB, 4 pages
This guidance produced by the Advisory Committee on Dangerous Pathogens’ Transmissible Spongiform Encephalopathy (ACDP TSE) Risk Management Subgroup aims to help minimise the risk of transmission of CJD and vCJD in healthcare and other work settings.
Published: 27 November 2012
Updated: 10 August 2017
- Added explanatory diagrams to Annex J.
- Added updated document: Annex F: Endoscopy.
- Uploaded updated versions of Annex A1, Annex F and the Acknowledgements.
- Sections on Infection control and annexes C and F have been updated to reflect the latest scientific research.
- Updated version of Annex J on Presurgical Assessment
- First published.